ESTRO 35 2016 _____________________________________________________________________________________________________ volume targets in the IBCL seed group and the loose seed group. Brachytherapy was performed using a dynamic dose calculation technique. Computed tomography/magnetic resonance imaging fusion-based dosimetry was performed 1 month after brachytherapy. Post-implant dose volume histogram (DVH) parameters, prostate sector dosimetry, operation time, seed migration, and toxicities were compared between the two groups. A sector analysis tool was used to divide the prostate into six sectors (anterior and posterior sectors at the base, mid-gland, and apex). Analyses were performed using the 2-sample t test for continuous data that followed a normal distribution, the Mann-Whitney test for continuous data that did not follow a normal distribution, and the Chi-squared test for categorical data. Probability (P) values of < 0.05 were considered significant.
Results:
In prostate sector dosimetry, V100 (95.3% vs. 89.7%; P = 0.014) and D90 (169.7 Gy vs. 152.6 Gy; P = 0.013) in the anterior base sector were significantly higher in the IBCL seed group than in the loose seed group. Other post-implant DVH parameters did not differ significantly between the two groups. The seed migration rate was significantly lower in the IBCL seed group than in the loose seed group (6% vs. 66%; P < 0.001). There was no significant difference in mean operation time between the two groups; however, mean operation time per seed was significantly longer in the IBCL seed group than in the loose seed group (1.31 min vs. 1.13 min; P = 0.003). The median follow-up was 18 months (range, 1-36 months). No significant differences in toxicities were seen between the two groups.
Conclusion:
Our study showed more dose coverage postoperatively in the anterior base prostate sector and less seed migration in IBCL seeds implantation compared to loose seeds implantation. Material and Methods: Template guided saturation biopsy was performed in 52 primary patients with suspicion to prostate cancer and PSA below 10 ng/ml. Biopsy was performed under US control with the help of brachytherapy grid and 5mm distance between samples. During positioning and biopsy procedure we put special attention for accurate sampling of prostate in periurethral region. The number of cores varied from 17 to 50 (average 33 cores). Finally in 31 patients with confirmed prostate cancer results of biopsy were used for brachytherapy planning.
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Results: Saturation biopsy revealed prostate cancer in 31 of 52 evaluated patients. Involved volume ranged from 5% to 100% (average -57%). Focal nature of PC diagnosed in 6 (19.4%), multifocal -in another 25 (80.6%) patients. Hemigland invasion mentioned in 10 cases. Saturation biopsy detected PC in periurethral cores in 22 (70.9%) of 31 evaluated patients: invasion of one core revealed in 1, 2 cores -in 6, 3 and more cores -in another 14 cases. In 10 patients extent of involvement in periurethral cores varied between 10% and 50%, in another 12 observations exceeded 50%. According to results obtained on saturation biopsy we performed HDR brachytherapy with "urethra low dose tunnel" (D10ur ≤80%) in 9 patients with noninvolved periurethral cores. Theoretically hemigland brachytherapy was possible in 10 of 31 evaluated patients. 
Material and Methods:
The previous radical treatments were: 3 Low dose rate BT (LDR-BT) (145 Gy), one combined treatment with external radiotherapy (EBRT) (45 Gy) and LDR-BT (100 Gy), and 7 EBRT (68-74 Gy). Four patients have been rescued with LDR-BT and seven with High-Dose-Rate-BT (HDR-BT). All patients have a complete study with abdominal CT scan, pelvic MRI, and bone scan to diagnose local disease exclusively. LDR-BT patients received 145 Gy with 125I. HDR patients, has been treated with 30 Gy in 3 fractions of 10 Gy separated ten days. Median time to Biochemical failure (BF) from the first treatment was 48 months (12-114). All patients received previous hormonotherapy. Median time to rescue was 69 months (33-156). Toxicities were evaluated according with CTCAE scale (version 4.0).
Results:
Median follow-up: 26,5 months (3-72 m). The overall survival time was 98 months (65-174). At the end of the follow up, March of 2015, all patients are alive, nine (82%) without evidence of disease, one patients had a retroperitoneal failure 7 months after the salvage-BT and other patient was diagnosed of a solitary bone metastases at 12 months. Median PSA nadir post-salvage-BT was 0.1 ng/ml (0-0,29). There were not grade 3 GU or GI toxicities. 100 % of LDR-BT patients presented acute GU-toxicity grade 2. Fiftyseven % of the HDR-BT patients had GU-toxicity grade 1 (0% grade 2).
Conclusion:
Prostate BT is an effective and well tolerated reirradiation treatment in local-recurrent prostate cancer patients, with, few long-term toxicities, mainly in those treated with HDR-BT.
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